Valion Bio (VBIO) Total Debt (2022)
Valion Bio (VBIO) posted Total Debt of $450000.0 for Q4 2022.
Powered by 
Analysis
Valion Bio (VBIO) Total Debt (2022) Analysis & Trends
Valion Bio has reported Total Debt for 1 years, with the latest figure at $450000.0 in Q4 2022.
- On a quarterly basis, Total Debt changed N/A year-over-year to $450000.0 in Q4 2022; TTM through Dec 2022 was $450000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $450000.0, changed N/A from the prior year.
- Total Debt was $450000.0 for Q4 2022 at Valion Bio.
- The five-year high for Total Debt was $450000.0 in Q4 2022, with the low at $450000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 62.75 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 28.66 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 8.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | - |